Recurrent Clostridium difficile infection: From colonization to cure

被引:74
|
作者
Shields, Kelsey [1 ]
Araujo-Castillo, Roger V. [2 ]
Theethira, Thimmaiah G. [1 ]
Alonso, Carolyn D. [2 ]
Kelly, Ciaran P. [1 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA
关键词
Antibiotic; Fecal microbiota therapy; Infection control; Infectious diarrhea; Nosocomial infection; Toxin; FECAL MICROBIOTA TRANSPLANTATION; IN-VITRO ACTIVITIES; ANTIBIOTIC-ASSOCIATED DIARRHEA; RISK-FACTORS; DOUBLE-BLIND; TOXIN-A; PSEUDOMEMBRANOUS COLITIS; BINARY TOXIN; INTESTINAL MICROBIOTA; TREATMENT STRATEGIES;
D O I
10.1016/j.anaerobe.2015.04.012
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:59 / 73
页数:15
相关论文
共 50 条
  • [31] Stool transplant for recurrent Clostridium difficile infection
    Rosien, U.
    Hagel, S.
    Goetz, M.
    GASTROENTEROLOGE, 2015, 10 (02): : 122 - 126
  • [32] Treatment of Recurrent and Severe Clostridium Difficile Infection
    Keller, J. J.
    Kuijper, E. J.
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 373 - 386
  • [33] Antidepressant Medications and Recurrent Clostridium difficile Infection
    Abdelfatah, Mohamed
    Nayfe, Rabih
    Enriquez, Kathleen
    Nijim, Ala
    El Zoghbi, Maysaa
    Watkins, Richard
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S208 - S208
  • [34] Incidence of diverticulosis in recurrent Clostridium difficile infection
    Lipp, Michael
    Pagovich, Odelya
    Min, Albert
    Bodenheimer, Henry
    Bernstein, Brett
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S193 - S194
  • [35] Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection
    Arkkila, Perttu E.
    Uusitalo-Seppala, Raija
    Lehtola, Laura
    Moilanen, Veikko
    Ristikankare, Matti
    Mattila, Eero J.
    GASTROENTEROLOGY, 2010, 138 (05) : S5 - S5
  • [36] Prediction of Clostridium difficile infection based on gut microbial traits in patients with Clostridium difficile colonization
    Dong Yan
    Yan-Di Huang
    Yun-Bo Chen
    Tao Lv
    Chun-Xia Zhu
    Jian-Rong Huang
    Lan-Juan Li
    Hepatobiliary&PancreaticDiseasesInternational, 2021, 20 (03) : 298 - 300
  • [37] Recurrent Clostridium difficile infection treated with bezlotoxumab
    Palenzuela Afonso, Beatriz
    Caparros Nieto, Ana B.
    Gonzalez Cruz, Macarena
    Martinez Faci, Cristina
    ANALES DE PEDIATRIA, 2023, 98 (01): : 141 - 142
  • [38] Treatment of refractory and recurrent Clostridium difficile infection
    Surawicz, Christina M.
    Alexander, Jacob
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (06) : 330 - 339
  • [39] Effectiveness of FMT in recurrent Clostridium difficile infection
    P Grzesiowski
    A Hermann
    A Dubaniewicz
    J Kasprzyk
    D Pawlik
    Z Zak-Pulawska
    Antimicrobial Resistance and Infection Control, 4 (Suppl 1)
  • [40] Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
    Wilcox, M. H.
    Gerding, D. N.
    Poxton, I. R.
    Kelly, C.
    Nathan, R.
    Birch, T.
    Cornely, O. A.
    Rahav, G.
    Bouza, E.
    Lee, C.
    Jenkin, G.
    Jensen, W.
    Kim, Y. -S.
    Yoshida, J.
    Gabryelski, L.
    Pedley, A.
    Eves, K.
    Tipping, R.
    Guris, D.
    Kartsonis, N.
    Dorr, M. -B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04): : 305 - 317